argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
766.92
-4.61 (-0.60%)
At close: Feb 27, 2026, 4:00 PM EST
766.70
-0.22 (-0.03%)
After-hours: Feb 27, 2026, 7:39 PM EST
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
$2,656,692
Profits / Employee
$808,027
Market Cap
47.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,599 | 451 | 39.29% |
| Dec 31, 2023 | 1,148 | 305 | 36.18% |
| Dec 31, 2022 | 843 | 193 | 29.69% |
| Dec 31, 2021 | 650 | 314 | 93.45% |
| Dec 31, 2020 | 336 | 148 | 78.72% |
| Dec 31, 2019 | 188 | 83 | 79.05% |
| Dec 31, 2018 | 105 | 32 | 43.84% |
| Dec 31, 2017 | 73 | 15 | 25.86% |
| Dec 31, 2016 | 58 | 17 | 41.46% |
| Dec 31, 2015 | 41 | 9 | 28.13% |
| Dec 31, 2014 | 32 | 10 | 45.45% |
| Dec 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
ARGX News
- 1 day ago - RBC Capital Lowers Price Target for argenx (ARGX) Amidst Maintained 'Outperform' Rating | ARGX ... - GuruFocus
- 1 day ago - Wells Fargo Lowers Price Target for argenx (ARGX) but Maintains Overweight Rating | ARGX Stock News - GuruFocus
- 1 day ago - ARGX Stock Rating Update: Citizens Raises Price Target to $944 | ARGX Stock News - GuruFocus
- 1 day ago - These Analysts Revise Their Forecasts On Argenx After Q4 Earnings - Benzinga
- 1 day ago - These Analysts Revise Their Forecasts On Argenx After Q4 Earnings - Benzinga
- 1 day ago - ARGX: Guggenheim Lowers Price Target While Maintaining 'Buy' Rating | ARGX Stock News - GuruFocus
- 1 day ago - ARGX: Baird Maintains 'Neutral' Rating, Price Target Raised to $867 | ARGX Stock News - GuruFocus
- 1 day ago - Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades - Seeking Alpha